Takashi Hatano1, Mahito Atsuta2, Hiroyuki Inaba2, Katsuhisa Endo2, Shin Egawa3. 1. Department of Urology, JR Tokyo General Hospital, 2-3-1 Yoyogi Shibuya-ku, Tokyo, 151-8528, Japan. hatano-t@jreast.co.jp. 2. Department of Urology, JR Tokyo General Hospital, 2-3-1 Yoyogi Shibuya-ku, Tokyo, 151-8528, Japan. 3. Department of Urology, Jikei University School of Medicine, Tokyo, Japan.
Abstract
BACKGROUND: The aim of this study was to evaluate the influence of components of angiomyolipoma (AML) on the efficacy of everolimus. METHODS: We investigated a total of 40 patients with tuberous sclerosis complex (TSC) who had AML ≥4 cm in diameter. The components of the AML were determined using abdominal computed tomography (CT) images. The AML density was measured as the mean Hounsfield unit (HU) values of the whole area of the AML on axial CT images. We classified them into two groups, i.e., a lipid group with a predominant lipid component (HU ≤ -50) and a solid group with predominant vascular and muscle components (HU ≥30). For each patient, we measured the AML reduction rate and transition of the mean HU value. RESULTS: The mean reduction rate of AML in the lipid group was 24%, whereas it was 68% in the solid group (P < 0.001). The mean tumor density after 6 months was decreased in both groups. In particular, the density significantly decreased compared to the baseline in the solid group (P < 0.001). The tumor density did not change after 6 months in either group. CONCLUSION: The effect of everolimus on TSC-AML is mainly a reduction of the solid components consisting of angioma and leiomyoma. The tumor density at the start of treatment might be a predictive marker for the response to everolimus in TSC-AML.
BACKGROUND: The aim of this study was to evaluate the influence of components of angiomyolipoma (AML) on the efficacy of everolimus. METHODS: We investigated a total of 40 patients with tuberous sclerosis complex (TSC) who had AML ≥4 cm in diameter. The components of the AML were determined using abdominal computed tomography (CT) images. The AML density was measured as the mean Hounsfield unit (HU) values of the whole area of the AML on axial CT images. We classified them into two groups, i.e., a lipid group with a predominant lipid component (HU ≤ -50) and a solid group with predominant vascular and muscle components (HU ≥30). For each patient, we measured the AML reduction rate and transition of the mean HU value. RESULTS: The mean reduction rate of AML in the lipid group was 24%, whereas it was 68% in the solid group (P < 0.001). The mean tumor density after 6 months was decreased in both groups. In particular, the density significantly decreased compared to the baseline in the solid group (P < 0.001). The tumor density did not change after 6 months in either group. CONCLUSION: The effect of everolimus on TSC-AML is mainly a reduction of the solid components consisting of angioma and leiomyoma. The tumor density at the start of treatment might be a predictive marker for the response to everolimus in TSC-AML.
Authors: John J Bissler; John Christopher Kingswood; Elżbieta Radzikowska; Bernard A Zonnenberg; Michael Frost; Elena Belousova; Matthias Sauter; Norio Nonomura; Susanne Brakemeier; Petrus J de Vries; Noah Berkowitz; Sara Miao; Scott Segal; Severine Peyrard; Klemens Budde Journal: Nephrol Dial Transplant Date: 2015-07-08 Impact factor: 5.992
Authors: Elieser Hitoshi Watanabe; Fernando Morbeck Almeida Coelho; Hilton Leão Filho; Bruno Eduardo Pedroso Balbo; Precil Diego Miranda de Menezes Neves; Fernanda Maria Franzin; Fernando Ide Yamauchi; Luiz Fernando Onuchic Journal: Sci Rep Date: 2021-04-19 Impact factor: 4.379